MedBioSphere
Articles Videos The Web  
    

The International Myeloma Foundation

Selected Abstract

The International Myeloma Foundation Applauds Expansion of VELCADE(R) for Previously Untreated Patients in Europe and Canada.
VELCADE Approval as an Initial Treatment Broadens Options for Patients NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the ...
September 29, 2008; Business Wire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. The International Myeloma Foundation Honors Dr. David Agus for Use of World's Most Powerful Magnets to Unlock Secrets of Cancer Treatment - Nov. 12, Beverly Hilton.
2. The International Myeloma Foundation Establishes First-of-a-Kind Partnership With Nurses to Enhance Patient Care.
3. The International Myeloma Foundation Advocates Formal Approval of Thalomid(R) for Multiple Myeloma.
4. The International Myeloma Foundation Says Major Medical Conference Points to Improved Treatment and Survival Options for Blood Cancers.(Conference news)
5. The International Myeloma Foundation Says REVLIMID(R) Meets Important Quality of Life Measures.
6. The International Myeloma Foundation Says Newly Diagnosed Patients Could Benefit from FDA "Priority Review" of VELCADE(R) for Front-Line Use.
7. The International Myeloma Foundation Says New Findings Reported at Global Cancer Conference Require New Ways to Evaluate Treatments.(Conference news)
8. The International Myeloma Foundation's 2006 Gala to Honor the Scientists of Bank On A Cure(R) -- The World's First Myeloma-Patient Gene Bank.
9. The International Myeloma Foundation: Multiple Studies at Global Cancer Conference Show New Therapies Changing the Outlook for Patients With Blood Cancers.
10. The International Myeloma Foundation Says New Thalidomide Data Confirms Survival Benefits for Older Patients.